Under the arrangement, prices for GLP-1 drugs—used both for diabetes and obesity—will be slashed for Medicare and Medicaid ...

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

Popular GLP-1 drugs like Ozempic will get cheaper in exchange for partial Medicare coverage, opening up new markets for Eli ...

The deal is with drugmakers Eli Lilly and Novo Nordisk to cut prices of their weight-loss drugs and expand Medicare coverage ...

Even after Trump’s new deal, obesity drugs are still too expensive.

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...

Trump announced big discounts to popular weight loss drugs Wegovy and Zepbound (also available for Diabetes treatment under ...

Now the entire country knows (or at least believes) that Steven Cheung, 43, a longtime comms staffer and attackdog for Trump ...

America's obesity epidemic costs an estimated $173 billion each year. The benefits of covering GLP-1s vastly outweigh the ...

Denmark-based Novo Nordisk, which makes Ozempic, Rybelsus and Wegovy; and Indianapolis-based Eli Lilly, which makes Zepbound, ...

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...